Mabpharm Limited (HK:2181) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Mabpharm Limited has announced the early termination of a tenancy agreement between its subsidiary Biomabs and Shengheng Biotech, initially set to end in December 2024. The termination agreement allows Shengheng Biotech to vacate the premises by September 30, 2024, and is considered beneficial for the Group as it coincides with Biomabs’ new business developments and the securing of a more favorable lease nearby. The decision was made in the interest of the shareholders and the Group, following arm’s length negotiations.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.